The Steno Opti-Bolus-Timing Studies

NCT ID: NCT07021690

Last Updated: 2025-06-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-06-30

Study Completion Date

2027-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The project investigates the significance of the timing of insulin dosing for breakfast and lunch with an automated insulin pump and whether it matters if the meal primarily contains high or low glycemic index carbohydrates.

We hypothesise that a bolus given 15 minutes before the meal will result in the best blood glucose levels after the meal, regardless of the type of carbohydrates.

Participants will attend 6 experimental days over a maximum of 3 months, where they will be served either breakfast or lunch at the research site, depending on sub-study (breakfast or Lunch sub-study). Three different bolus timings will be tested, with either rapidly absorbed carbohydrates or slowly absorbed carbohydrates, in a randomized order for each participant. Participants will take insulin for the meal using the bolus calculator in the pump, either 15 minutes before, at the start of the meal, or 30 minutes after the meal. The development in sensor glucose will then be monitored for up to 4 hours after the meal.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 1 Diabetes (T1D)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

the study contains two sub-studies: breakfast and lunch
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Start high-GI

T=0: having already rested for 30 min, the participant continues to rest T=15: meal bolus for high GI meal, meal starts T=30: meal ends

Group Type ACTIVE_COMPARATOR

High glyceamic index meal

Intervention Type OTHER

Meal sizes are standardized regarding the amount of carbohydrate, always 50 g. The composition of these meals focuses on selecting carbohydrates with high glycemic index.

Pre high-GI

T=0: meal bolus for high GI meal T=15: meal starts T=30: meal ends

Group Type EXPERIMENTAL

High glyceamic index meal

Intervention Type OTHER

Meal sizes are standardized regarding the amount of carbohydrate, always 50 g. The composition of these meals focuses on selecting carbohydrates with high glycemic index.

Post high-GI

T=0: having already rested for 30 min, the participant continues to rest T=15: meal starts T=30: meal ends T=45: meal bolus for high GI meal

Group Type EXPERIMENTAL

High glyceamic index meal

Intervention Type OTHER

Meal sizes are standardized regarding the amount of carbohydrate, always 50 g. The composition of these meals focuses on selecting carbohydrates with high glycemic index.

Pre low-GI

T=0: meal bolus for low GI meal T=15: meal starts T=30: meal ends

Group Type EXPERIMENTAL

Low glyceamic index meal

Intervention Type OTHER

Meal sizes are standardized regarding the amount of carbohydrate, always 50 g. The composition of these meals focuses on selecting carbohydrates with low glycemic index.

Start low-GI

T=0: having already rested for 30 min, the participant continues to rest T=15: meal bolus for low GI meal, meal starts T=30: meal ends

Group Type EXPERIMENTAL

Low glyceamic index meal

Intervention Type OTHER

Meal sizes are standardized regarding the amount of carbohydrate, always 50 g. The composition of these meals focuses on selecting carbohydrates with low glycemic index.

Post low-GI

T=0: having already rested for 30 min, the participant continues to rest T=15: meal starts T=30: meal ends T=45: meal bolus for low GI meal

Group Type EXPERIMENTAL

Low glyceamic index meal

Intervention Type OTHER

Meal sizes are standardized regarding the amount of carbohydrate, always 50 g. The composition of these meals focuses on selecting carbohydrates with low glycemic index.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

High glyceamic index meal

Meal sizes are standardized regarding the amount of carbohydrate, always 50 g. The composition of these meals focuses on selecting carbohydrates with high glycemic index.

Intervention Type OTHER

Low glyceamic index meal

Meal sizes are standardized regarding the amount of carbohydrate, always 50 g. The composition of these meals focuses on selecting carbohydrates with low glycemic index.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Type 1 diabetes ≥ 3 years Age 18-70 years User of the MiniMed 780G for at least 3 months Use of Novorapid insulin in the pump (for a minimum of two weeks) TIR \> 70% for minimum of 14 days Use carbohydrate counting and bolus calculation Uploads insulin pump and CGM data to the Carelink Personal database Pump settings: carbohydrate ratio (300-500 rule), active insulin time of ≤ 3 hours and smartguard target glucose of 5.5 or 6.1 mmol/L

Exclusion Criteria

Use of anti-diabetic medicine (other than insulin), corticosteroids or other drugs affecting glucose metabolism during the study period or within 4 weeks prior to study start Diagnosed with gastroparesis Females who are pregnant, breast-feeding Food allergies related to standardized meals Alcohol or drug abuse Inability to understand the individual information and to give informed consent.

Current participation in another clinical trial that, in the judgment of the principal investigator, will compromise the study results
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Steno Diabetes Center Copenhagen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Kirsten Nørgaard

MD, DMSc

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kirsten Nørgaard, Professor

Role: PRINCIPAL_INVESTIGATOR

Steno Diabetes Center Copenhagen Clinical Translational Research, Diabetes Technology

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Steno Diabetes Center Copenhagen Clinical Translational Research, Diabetes Technology

Herlev, , Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Karen Rytter, RN, PhD

Role: CONTACT

+45 39680800

Ajenthen Ranjan, MD, PhD

Role: CONTACT

+45 39680800

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Copenhagen University Hospital

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The TiMeD-T1D Project
NCT07172672 NOT_YET_RECRUITING NA